SCHEMBL3540378

SCHEMBL3540378

CCCCc1nc(-c2ccc(C(F)(F)F)cc2)sc1COc1ccc(C#N)c([S+](C)[O-])c1

nearest known ligand 0.42

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
PPARD Q03181 14/20 0.42
PPARA Q07869 9/20 0.42
PPARG P37231 6/20 0.42
FFAR1 O14842 7/20 0.40
ATP4A P20648 2/20 0.36
ATP4B P51164 2/20 0.36
CHRM5 P08912 1/20 0.34
SLC6A3 Q01959 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3542140 0.87 PPARD (0.49) PPARDPPARAPPARGFFAR1ATP4A
SCHEMBL3539378 0.87 PPARD (0.45) PPARDPPARAPPARGFFAR1ATP4A
SCHEMBL13787895 0.86 PPARD (0.46) PPARDPPARAPPARGFFAR1ATP4A
SCHEMBL3537453 0.86 PPARD (0.44) PPARDPPARAPPARGFFAR1ATP4A
SCHEMBL3536743 0.84 PPARD (0.44) PPARDPPARAPPARGFFAR1ATP4A
SCHEMBL13341970 0.83 PPARD (0.42) PPARDPPARAPPARGFFAR1CHRM5
SCHEMBL5433317 0.80 PPARD (0.41) PPARDPPARAPPARGFFAR1CHRM5
SCHEMBL3538554 0.80 PPARD (0.39) PPARDPPARAPPARGFFAR1CHRM5
SCHEMBL3537011 0.79 CYP11B1 (0.41) PPARDPPARAPPARGFFAR1ATP4A
SCHEMBL27768640 0.79 PPARD (0.38) PPARDPPARAPPARGFFAR1CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
US-7709509-B2 Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-05-04 US disclosed
EP-2083006-A1 Oxadiazolones, processes for their preparation and their use as pharmaceuticals Sanofi-Aventis Deutschland GmbH (DE) 2009-07-29 EP disclosed
EP-2083006-A1 Oxadiazolones, processes for their preparation and their use as pharmaceuticals Sanofi-Aventis Deutschland GmbH (DE) 2009-07-29 EP disclosed
EP-1740583-B1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-01 EP disclosed
EP-1740583-B1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-01 EP disclosed
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-23 US disclosed
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-23 US disclosed
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-23 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-10-16 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-02 US disclosed
EP-1740583-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS Sanofi-Aventis Deutschland GmbH (DE) 2007-01-10 EP disclosed
WO-2005097786-A1 OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179191-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS PPARD, PPARA, PPARG PPARD 1/4885PPARA 2/4885PPARG 3/4885
US-20080255212-A1 OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS PPARD, PPARG, PPARA PPARD 1/4885PPARA 3/4885PPARG 2/4885
US-20080262052-A1 METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS PPARD, PPARG, PPARA PPARD 1/4885PPARA 3/4885PPARG 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.